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To identify predictive molecular markers for gemcitabine resistance, we investigated changes in the expression of four genes
associated with gemcitabine transport and metabolism during the development of acquired gemcitabine resistance of pancreatic
cancer cell lines. The expression levels of human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (dCK), RRM1,
and RRM2 mRNA were analysed by real-time light cycler-PCR in various subclones during the development of acquired resistance to
gemcitabine. Real-time light cycler-PCR demonstrated that the expression levels of either RRM1 or RRM2 progressively increased
during the development of gemcitabine resistance. Expression of dCK was slightly increased in cells resistant to lower concentrations
of gemcitabine, but was decreased below the undetectable level in higher concentration-resistant subclones. Expression of hENT1
was increased in the development of gemcitabine resistance. As acquired resistance to gemcitabine seems to correlate with the
balance of these four factors, we calculated the ratio of hENT1 dCK/RRM1 RRM2 gene expression in gemcitabine-resistant
subclones. The ratio of gene expression decreased progressively with development of acquired resistance in gemcitabine-resistant
subclones. Furthermore, the expression ratio significantly correlated with gemcitabine sensitivity in eight pancreatic cancer cell lines,
whereas no single gene expression level correlated with the sensitivity. These results suggest that the sensitivity of pancreatic cancer
cells to gemcitabine is determined by the ratio of four factors involved in gemcitabine transport and metabolism. The ratio of the four
gene expression levels correlates with acquired gemcitabine-resistance in pancreatic cancer cells, and may be useful as a predictive
marker for the efficacy of gemcitabine therapy in pancreatic cancer patients.
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Pancreatic adenocarcinoma is a common cancer with extremely
poor prognosis. In the past few years, gemcitabine, a novel
pyrimidine nucleoside analogue, has become the standard
chemotherapeutic agent used in patients with pancreatic cancer
(Rothenberg et al, 1996; Burris et al, 1997). However, even with
this drug, most pancreatic adenocarcinomas exhibit an inexorable
disease progression, and the clinical impact of gemcitabine
remains modest owing to a high degree of inherent and acquired
chemoresistance (Carmichael et al, 1996; Li et al, 2004). No clinical
molecular markers have previously been shown that can predict a
benefit from gemcitabine chemotherapy, and patients are treated
empirically until disease progression or worsening therapy
performance. Therefore, it is extremely important to determine
predictive molecular markers of gemcitabine resistance for more
effective treatment of these tumours.
Gemcitabine has a complex pathway of metabolism, and there
are many mechanisms that can contribute to gemcitabine
cytotoxicity and/or chemoresistance (Habiro et al, 2004; Koizumi
et al, 2005). In recent studies performed on human cancer cell
lines, human equilibrative nucleoside transporter-1 (hENT1) was
found to be the major gemcitabine transporter (Garcia-Manteiga
et al, 2003). If gemcitabine is not transported into the cell via
hENT1 it cannot inhibit cell growth (Mackey et al, 1998;
Rauchwerger et al, 2000), but increased hENT1 abundance
facilitates efficient cellular entry of gemcitabine and confers
increased cytotoxicity (Mackey et al, 1999; Ritzel et al, 2001).
Inside the cell, gemcitabine is phosphorylated by deoxycytidine
kinase (dCK) in a rate-limiting step. Deficiency in dCK activity has
been considered to be one of the main mechanisms responsible
for the development of resistance to gemcitabine. Another factor in
gemcitabine resistance is the overexpression of ribonucleotide
reductase (RR). Ribonucleotide reductase is mainly responsible for
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sthe conversion of ribonucleosides to deoxyribonucleoside tripho-
sphates (dNTPs), which are essential for DNA polymerisation and
repair (Cory and Sato, 1983; Thelander and Berg, 1986; Fan et al,
1996; Zhou et al, 1998). RR consists of the dimerised large and
small subunits, M1 and M2, respectively. The M1 subunit possesses
a binding site for enzyme regulation (regulatory subunit), and the
M2 subunit is involved with RR activity (catalytic subunit).
Although it has been proposed that the genes for gemcitabine
transport and metabolism are involved in the mechanism of
cellular resistance to gemcitabine, it is not fully understood how
gemcitabine influences its own transport and metabolism in the
process of acquired resistance. Understanding alterations in
expression of genes, which characterise the response of cancer
cells to gemcitabine treatment in the process of acquired
resistance, would allow us to improve therapeutic strategies for
pancreatic cancer.
In this study, we established various gemcitabine-resistant
subclones of human pancreatic cancer cell lines, and investigated
changes in gene expression associated with gemcitabine transport
and metabolism, that is, hENT1, dCK, RRM1, and RRM2 mRNA, in
the development of gemcitabine resistance. Quantitative RT–PCR
analysis showed that the balance of the four gene expression levels
is associated with inherent and acquired resistance to gemcitabine
in pancreatic cancer cells. Resistance of cancer cells to gemcitabine
is determined by the ratio of these gene expression levels, but not
predicted by that of a single gene. The ratio of gene expression
might be useful as a predictive marker for the efficacy of
gemcitabine therapy in pancreatic cancer patients.
MATERIALS AND METHODS
Chemicals
Gemcitabine was a gift from Eli Lilly Pharmaceuticals (Indiana-
polis, IN, USA). All other chemicals were of analytical grade and
commercially available.
Cell culture and establishment of gemcitabine-resistant
pancreatic cancer cells
Eight human pancreatic adenocarcinoma cell lines, PK1, PCI43,
KLM1, PK8, PK9, MIAPaCa2, KP1N, and BxPC3, were used in this
study. PK1, KLM1, PK8, and PK9 cell lines were obtained from
the Cell Resource Center for Biochemical Research (Tohoku
University, Sendai, Japan). KP1N and MIAPaCa2 cell lines were
purchased from the Health Science Research Resources Bank
(Osaka, Japan). The PCI43 cell line was provided by Dr H Ishikura
at Hokkaido University (Sapporo, Japan). PK1, PCI43, KLM1, PK8,
PK9, KP1N, and BxPC3 were grown in RPMI 1640 media (Gibco,
Paisley, Scotland) supplemented with 10% heat-inactivated fetal
bovine serum in a humidified 5% CO2 incubator at 371C. The
MIAPaCa2 cell line was cultured in Dulbecco’s modified Eagles
medium (DMEM). Gemcitabine-resistant cells were generated by
exposing the PCI43, PK1, and KLM1 cell lines to incrementally
increasing gemcitabine concentrations starting at 3nM. As the cells
adapted to the drug, the gemcitabine concentration was doubled.
The intermediate resistant variants were cultured for at least 4
weeks. The cell lines were named as follows: G for gemcitabine,
followed by the nM concentration at which the cell line grew
logarithmically. The most resistant variants were PCI43-G4000,
PK1-G4000, and KLM1-G4000 and were resistant to continuous
exposure to gemcitabine at 4000nM. Experiments were performed
using cells in the exponential phase of growth.
Drug cytotoxicity assay
The relative cytotoxicity of gemcitabine in each cell line was
assessed with a WST-1 assay using a Cell Counting Kit (Dojindo
Laboratories, Kumamoto, Japan). This assay is based on the
reduction of a tetrazolium compound to a soluble derivative by the
dehydrogenase enzymes of metabolically active cells. The absor-
bance (450nm) is directly proportional to the number of living
cells in culture. Cells were added to 96-well tissue culture plates
(3 10
3cells/well) overnight and exposed to increasing concentra-
tions (10
 210
3mM) of gemcitabine for 72h, after which the number
of remaining living cells was determined according to the
manufacturer’s instructions. Chemosensitivity was expressed as
the drug concentration that inhibited cell proliferation by 50%
(IC50 values) and was determined from concentration–effect
relationship.
Quantitative LightCycler RT–PCR
Total RNA was extracted from each cell line and gemcitabine-
resistant subclones using the RNeasy Protect Mini Kit (Qiagen,
Hilden, Germany) with the RNase-Free DNase Set (Qiagen)
according to the manufacturer’s instructions. Complementary
DNA (cDNA) was produced from 1mg of RNA using an Oligo
(dT)12 18 Primer (Invitrogen, Carlsbad, CA, USA) and MMLV
reverse transcriptase (Promega, Madison, WI, USA). Primers for
hENT1, dCK, RRM1, RRM2, and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were based on the sequence of each gene
(Entrez-PubMed) and designed by the program Primer 3.
Oligonucleotides used as PCR primers are summarised in Table 1.
Quantitative RT–PCR was performed in a LightCycler system
(Roche Molecular Biochemicals, Mannheim, Germany) using
SYBR Green fluorescence. In this system, all reactions were run
in glass capillaries with a total volume of 20ml. The reaction
mixture consisted of 2ml of FastStart DNA Master SYBR Green I,
SYBR Green I dye, and 10mM MgCl2 (Roche Diagnostics GmbH,
Mannheim, Germany). Primers were added to a final concentration
of 34mM. In each experiment, 1mg of extracted RNA from the cells
was reverse transcribed to generate cDNAs that were then diluted
1:10. Finally, 5ml of the diluted cDNA was added to a capillary
tube. One positive control, one negative control, and standards
were included in each run. The PCR programs started with a
preincubation step for activation of the FastStart enzyme, then
continued with amplification, and ended with melting curve
analysis. The temperature transition rate was 0.11Cs
 1. The
preincubation and amplification programmes for each line were
as follows: hENT1, preincubation at 951C for 10min
and amplification with 40 cycles of 951C for 10s, 601C for 10s,
and 721C for 10s; dCK, preincubation at 951C for 10min and
amplification with 40 cycles of 951C for 10s, 561C for 10s,
and 721C for 17s; RRM1, preincubation at 951C for 10min and
amplification with 40 cycles of 951C for 10s, 581C for 10s,
and 721C for 10s; RRM2, preincubation at 951C for 10min and
amplification with 40 cycles of 951C for 10s, 601C for 10s,
and 721C for 6s; GAPDH, preincubation at 951C for 10min and
amplification with 40 cycles of 951C for 10s, 551C for 10s, and
721C for 13s. All programs were then followed by a heating step at
951C and a cooling step at 651C for 15s each. Each experiment
Table 1 Sequences of primers used in reverse transcription–PCR
Gene Forward primer (50–30) Reverse primer (50 –30)
hENT1 AAAGGAGAGGAGCCAAGAGC GGCCCAACCAGTCAAAGATA
dCK CCCGCATCAAGAAAATCTCC TCATCCAGTCATGCCAGTC
RRM1 GGAGGAATTGGTGTTGCTGT GCTGCTCTTCCTTTCCTGTG
RRM2 CCCGCTGTTTCTATGGCTTC CCCAGTCTGCCTTCTTCTTG
GAPDH ATGACCACAGTCCATGCCAT TTGAAGTCAGAGGAGACCAC
Abbreviations: dCK¼deoxycytidine kinase; GAPDH¼glyceraldehyde-3-phosphate
dehydrogenase; hENT1¼human equilibrative nucleoside transporter-1.
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susing quantitative RT–PCR was performed in triplicate. The
expression of hENT1, dCK, RRM1, and RRM2 mRNA was
quantified relative to GAPDH expression.
The Roche software uses the second derivative maximum
method to calculate the fractional cycle numbers where the
fluorescence rises above background (crossing point, Cp), that is,
the point at which the rate of change of fluorescence is fastest. For
the standard curve, CpS are plotted vs log concentration for the
standards. This standard curve is used to estimate the concentra-
tion of each sample. The standard curves were saved in a
coefficient file that was used by the relative quantification software
from Roche to calculate the mRNA levels relative to GAPDH. This
program also corrected for the differences in efficiency of the PCR
reaction for each target.
Statistical analysis
Data are expressed as means7s.d. Analysis was performed using
the Mann–Whitney U-test (two-tailed) for nonparametric data.
Correlations between nonparametric data were analysed by the
Spearman correlation test.
RESULTS
Development of acquired gemcitabine resistance in
pancreatic cancer cell lines, PCI43, PK1, and KLM1
Resistance to gemcitabine was successfully induced in the PCI43,
PK1, and KLM1 cell lines via exposure to stepwise increases in
gemcitabine concentration. Gemcitabine-resistant PCI43, PK1, and
KLM1 cells were developed by continuous exposure to increasing
concentrations of gemcitabine over a period of 6 months, starting
with an initial concentration of 3nM. The resistant cells obtained,
PCI43-G4000, PK1-G4000, and KLM1-G4000, were viable in
medium containing 4000nM gemcitabine. Resistant cells showed
no apparent morphologic differences or difference in growth rate
compared with the parental cells.
The IC50 values and resistance ratios for parental cells and
gemcitabine-resistant cells are listed in Table 2. The IC50 values of
gemcitabine for the parental PCI43, PK1, and KLM1 cells were 350,
160, and 80nM, respectively. PCI43-G4000, PK1-G4000, and KLM1-
G4000 cells were 157-, 625-, and 2625-fold less sensitive to
gemcitabine than the parental cell lines, respectively.
Analysis of hENT1, dCK, RRM1, and RRM2 mRNA
expression by real-time light cycler-PCR in different
gemcitabine-resistant cell lines
To evaluate the expression of hENT1, dCK, RRM1, and RRM2
mRNA, real-time light cycler-PCR was performed in a quantitative
manner. The mRNA was extracted from each gemcitabine-resistant
cell line and analysed via light cycler. Glyceraldehyde-3-phosphate
dehydrogenase was used as an internal control. The quantitative
data were summarised from the means of the data gathered from
the three experiments (Figure 1). Real-time light cycler-PCR
demonstrated that PCI43-G4000 cells had approximately 4- and
10-fold increases in the levels of RRM1 and RRM2 mRNA
compared with the parental cells, respectively. PK1-G4000 cells
had approximately a two-fold increase in levels of RRM1 mRNA,
but there was no increase of RRM2 mRNA compared with parental
cells. Similarly, KLM1-G4000 cells had approximately a 42-fold
increase in levels of RRM1 mRNA, but no increase of RRM2 mRNA
compared with parental cells. Human equilibrative nucleoside
transporter-1 gene expression was significantly increased com-
pared with parental cells in PCI43-G4000 and KLM1-G4000 cells,
but not in PK1-G4000 cells. Expression of dCK mRNA was not
detected by real-time light cycler-PCR in either PCI43-G4000 or
PK1-G4000 cells, and no changes in dCK mRNA expression were
observed in KLM1-G4000 cells. To determine the cellular
modification responsible for dCK mRNA downregulation, seven
exons of the dCK gene as well as the 50-untranslated regions were
amplified by PCR as described previously (Galmarini et al, 2004).
In PCR products obtained using genomic DNA from cells, as
shown in Figure 2, a partial deletion of the dCK gene was amplified
in both PCI43-G4000 and PK1-G4000 cells. No deletion of the dCK
gene was detected in parental cell lines or KLM1-G4000 cells.
Gene expression changes in the process of acquired
gemcitabine resistance by real-time light cycler-PCR in
pancreatic cancer cells
It is not fully understood how gemcitabine influences its own
transport and metabolism in the development of gemcitabine
resistance. To clarify the changes of gene expression in the process
of acquired resistance, we established seven gemcitabine-resistant
subclones of the PCI43, PK1, and KLM1 cell lines. Examination of
the gemcitabine-resistant PCI43 subclones revealed a proportional
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Figure 1 mRNA expression relative to GAPDH in parental and
gemcitabine-resistant cells of PCI43, PK1, and KLM1 cell lines, respectively.
Each IC50 value is the mean of the values in three independent sensitivity
tests performed in quadruplicate. Expression levels are relative to
expression of GAPDH. *Po0.05 to parental cells. Bars, s.d.
Table 2 IC50 values of gemcitabine in parental and gemcitabine-resistant
cells of PCI43 and PK1 cell lines
Cell lines IC50 (nM) of GEM Resistant ratio
PCI43 350
PCI43–G4000 55000 157
PK1 160
PK1–G4000 100000 625
KLM1 80
KLM1–G4000 210000 2625
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sincrease in RRM2 message with increasing gemcitabine exposure
(Figure 3). RRM1 mRNA showed a two- to four-fold up regulation
of expression levels. Significant increases in RRM1 and RRM2 gene
expression induced by gemcitabine were detected in the subclones
PCI43-G30 and -G3, respectively. No dCK mRNA could be detected
in subclones PCI43-G3000 and -G4000, which had higher
resistance to gemcitabine, but the dCK gene was slightly increased
at lower concentrations of gemcitabine. The hENT1 gene was
slightly increased in the latter phase of development of acquired
resistance. In the gemcitabine-resistant PK1 subclones, a slight
increase in RRM1 mRNA was detected, but no increase in the
RRM2 gene was observed. No dCK mRNA could be detected in
subclones PK1-G300 to -G4000. The gemcitabine-resistant KLM1
subclones showed marked upregulation in RRM1 mRNA, but there
was no increase in the RRM2 gene. dCK mRNA could be detected
in all KLM1 subclones. These results suggest that acquired
resistance of pancreatic cancer cells to gemcitabine may be
determined by the balance of these four factors, but is not
predicted by that of a single gene. Decreased hENT1 or dCK has
been reported to promote gemcitabine resistance (Ruiz van
Haperen et al, 1994; van der Wilt et al, 2000; Garcia-Manteiga
et al, 2003; Jordheim et al, 2003; Galmarini et al, 2004). In contrast,
increased expression of RR has been reported to be associated with
gemcitabine resistance in human tumour cells (Goan et al, 1999;
Jung et al, 2001). For these reasons, we calculated the ratio of
hENT1 dCK/RRM1 RRM2 gene expression in gemcitabine-
resistant subclones. As shown in Figure 4, the ratio of hENT1 
dCK/RRM1 RRM2 expression progressively decreased in the
process of acquired gemcitabine resistance.
Correlation of the hENT1 dCK/RRM1 RRM2 ratio with
gemcitabine chemosensitivity in pancreatic cancer cell
lines
To determine whether the hENT1 dCK/RRM1 RRM2 ratio
correlated with gemcitabine sensitivity, we examined the relative
mRNA expression of hENT1, dCK, RRM1, and RRM2 to GAPDH
in eight human pancreatic cancer cell lines. Correlations of IC50
values and relative levels of gene expression in each cell lines
are summarised in Table 3. We found that the IC50 values of
gemcitabine did not significantly correlate with relative expression
levels of hENT1, dCK, RRM1,o rRRM2. Next, the ratio of
hENT1 dCK/RRM1 RRM2 expression was calculated and the
correlation with gemcitabine sensitivity was determined (Figure 5).
Cells with a higher hENT1 dCK/RRM1 RRM2 expression
ratio showed higher gemcitabine chemosensitivity, whereas
cells with a lower ratio showed higher chemoresistance. The
PCI43 and PCI43-G4000
ex 1 ex 7 ex 2 ex 3 ex 4 ex 5 ex 6 5′-UTR
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Figure 2 Analysis of dCK PCR product of parental cells and PCI43-
G4000, PK1-G4000, and KLM1-G4000, on agarose gel electrophoresis
stained with ethidium bromide. The 50-untranslated region and complete
coding sequence of exons 1–7 of the human dCK gene were amplified.
P: parental cells, G: gemcitabine resistant.
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Figure 3 Relationship between gemcitabine resistance and expression levels of hENT1, dCK, RRM1, and RRM2 mRNA in the process of acquired
gemcitabine resistance in gemcitabine-resistant PCI43, PK1, and KLM1 subclones. Relative mRNA expression to GAPDH was calculated. The value of relative
mRNA expression in parental cells was assigned as 1.0. Each point represents the mean7s.d. of quadruplicate determinations per plate repeated in triplicate.
P: parental cells, G: gemcitabine-resistant. *Po0.05 to parental cells. Bars, s.d.
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shENT1 dCK/RRM1 RRM2 ratio significantly correlated with
the gemcitabine IC50 in eight pancreatic cancer cell lines
(P¼0.0029). Neither the RRM1 RRM2 ratio, the hENT1/
RRM1 RRM2 ratio, nor the dCK/RRM1 RRM2 ratio correlated
with sensitivity to gemcitabine.
DISCUSSION
Chemoresistance is a major cause of pancreatic adenocarcinoma
treatment failure with gemcitabine. The majority of patients with
gemcitabine-treated pancreatic adenocarcinoma become resistant
after consecutive treatments, and fail to derive benefit from
chemotherapy. Therefore, it is extremely important to clarify the
mechanism behind chemoresistance and to identify predictive
markers of inherent and acquired chemoresistance to gemcitabine
for better treatment of these tumours.
It has been shown that modulation of cellular enzymes of
gemcitabine transport and metabolism influences drug activity in
vitro (Mackey et al, 1998, 1999; Goan et al, 1999; Ritzel et al, 2001).
Cellular enzymes of gemcitabine transport and metabolism, that is,
hENT1, dCK, RRM1, and RRM2, are well documented. Moreover,
experimental data may improve the success of pancreatic cancer
treatment either by selecting responsive patients or by modulation
of gemcitabine effect with rationally selected drug combinations.
For these reasons, this study addressed the transcription analysis
of hENT1, dCK, RRM1, and RRM2 in parental cell lines and in
isolated variable resistant subclones continuously exposed to
gemcitabine to determine possible predictive markers for gemci-
tabine resistance. Our data demonstrate for the first time that
acquired and inherent chemoresistance of pancreatic cancer cells
to gemcitabine is determined by the balance of dCK, RRM1, RRM2,
and hENT1 gene expression, but not to that of any of the individual
genes. The hENT1 dCK/RRM1 RRM2 expression ratio signifi-
cantly correlates with resistance to gemcitabine in pancreatic
cancer cells, including acquired gemcitabine-resistant cells,
suggesting that a decrease of this ratio reflects inherent and
acquired chemoresistance of pancreatic cancer cells to gemcitabine
and may be a key to understanding the variable effectiveness
of gemcitabine among individual patients. The expression ratio is a
novel, informative marker for predicting and monitoring the
responses of pancreatic cancer patients to gemcitabine.
A recent study performed on cultured cancer cell lines indicated
that hENT1 is the major gemcitabine transporter in human
pancreatic cancer cells (Garcia-Manteiga et al, 2003). It is
speculated that populations of cells with lower hENT1 abundance
may be relatively gemcitabine resistant owing to reduced
intracellular accumulation. In fact, pharmacological inhibition of
hENT1 in cells has been reported to render them gemcitabine
resistant (Mackey et al, 1998). However, the current study shows
that expression of the hENT1 gene was not reduced in the
development of gemcitabine resistance, and did not correlate with
IC50 values of gemcitabine in eight pancreatic cancer cell lines.
Table 3 Relative hENT1, dCK, RRM1, and RRM2 mRNA expression to
GAPDH in human pancreatic cancer cell lines
Relative mRNA expression to GAPDH
Cell lines IC50 (nM) hENT1 dCK RRM1 RRM2
PCI43 350 1.0070.12 0.3670.0.3 0.4370.02 0.5070.04
PK1 160 1.0070.13 1.0070.16 1.0070.13 1.0070.21
KLM1 80 3.8870.22 0.8170.02 1.0870.04 1.4670.13
PK9 70 1.1270.17 0.9970.05 0.3170.02 0.6370.06
PK8 40 3.4570.28 2.5170.07 0.7170.04 1.8270.19
MIAPaCa2 40 2.6470.42 0.4270.08 0.4270.07 0.4770.04
KPIN 40 23.2671.33 2.5970.04 1.5870.02 4.3170.41
BxPC3 30 3.5270.51 1.2070.21 0.7070.08 0.8470.16
P-value to IC50 NS NS NS NS
NS: not significant. Abbreviations: dCK¼deoxycytidine kinase; GAPDH¼glycer-
aldehyde-3-phosphate dehydrogenase; hENT1¼human equilibrative nucleoside
transporter-1.
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Figure 4 Changes in the hENT1 dCK/RRM1 RRM2 expression ratio
in gemcitabine-resistant PCI43, PK1, and KLM1 subclones. Value of the ratio
in parental cells was set as 1.0. The ratio of hENT1 dCK/RRM1 RRM2
expression progressively decreased in the process of acquired gemcitabine
resistance. P: parental cells, G: gemcitabine resistant.
0
2
4
6
8
10
0 100 200 300 400
P = 0.0029
h
E
N
T
1
×
d
C
K
R
R
M
1
×
R
R
M
2
IC50 of gemcitabine (nM)
Figure 5 Significant correlation between the IC50 of gemcitabine and the
value of hENT1 dCK/RRM1 RRM2 expression ratio in eight pancreatic
cancer cell lines (P¼0.0029). Cells with a higher hENT1 dCK/
RRM1 RRM2 expression ratio showed higher gemcitabine chemosensi-
tivity, whereas cells with a lower ratio showed higher chemoresistance.
Predictive markers for gemcitabine chemoresistance
Y Nakano et al
461
British Journal of Cancer (2007) 96(3), 457–463 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sThese data suggest that hENT1 expression alone does not reflect
inherent and acquired resistance to gemcitabine. The increase in
hENT1 expression in the PK1-G4000, PCI-G4000, and KLM1-G4000
subclones may be regarded as a compensatory adaptation to
higher chemoresistance to gemcitabine.
Previous reports in cells and animal models cited dCK mutation/
deficiency as the main mechanism for gemcitabine resistance in cells
with an acquired resistance (Ruiz van Haperen et al, 1994; van der
Wilt et al, 2000; Galmarini et al, 2001; Jordheim et al,2 0 0 3 ) .I nt h i s
study, expression of the dCK gene was slightly increased in subclones
that were resistant to lower concentrations of gemcitabine, and was
undetectable in subclones with high resistance to gemcitabine, that
is, PCI43-G4000 and PK1-G4000. Furthermore, we found that
expression of the dCK gene alone does not correlate with sensitivity
to gemcitabine in eight pancreatic cancer cell lines. Deficiency of
dCK described in previous reports was mainly based on studies
performed on highly gemcitabine-resistant clones, and quite different
from the clinical setting. Our data indicate that dCK deficiency is
involved in a higher grade of acquired gemcitabine resistance, but
not in a lower grade of resistant cells or in parental cells.
Expression of RR has been reported to be one of the determinants
of gemcitabine chemoresistance in human tumour cells (Jung
et al, 2001). In fact, artificial overexpression of RRM2 results in a
further increase in gemcitabine chemoresistance (Goan et al, 1999).
An increased level of RR expands the size of the dNTP pools, which
competitively inhibits the incorporation of gemcitabine tripho-
sphate into DNA (Plunkett et al, 1996). The expanded dNTP pools
further downregulate the activity of dCK via a negative-feedback
pathway. Results from this study demonstrate that RRM1 mRNA
expression was markedly increased in the KLM1 gemcitabine-
resistant cells over that of the parental cells. This result supports the
previous report that RRM1 is the marker predicting resistance to
gemcitabine in lung cancer cell lines (Davidson et al, 2004). In this
study, KLM1 gemcitabine-resistant cells had no dCK deficiency in
contrast to the lack of dCK in PCI43 and PK1 gemcitabine-resistant
cells. Therefore, these data demonstrate that RRM1 may correlate
with acquired resistance to gemcitabine, especially in cells without
dCK deficiency. RRM2 mRNA was increased in PCI43 gemcitabine-
resistant cells, but not in PK1 and KLM1 gemcitabine-resistant
subclones. In the eight pancreatic carcinoma cells tested, the cells
with higher inherent resistance to gemcitabine did not show higher
levels of RRM1 and RRM2 expression. These results suggest that an
increase in either RRM1 or RRM2 expression alone correlates with
acquired chemoresistance, but does not reflect inherent chemo-
resistance to gemcitabine. In the development of gemcitabine
resistance, increases in either RRM1 or RRM2 expression, in
addition to a decrease in dCK, may indicate that cells are regulated
to avoid damage by gemcitabine incorporation in gemcitabine-
resistant cells.
Ribonucleotide reductase plays a role as a central enzyme
controlling the rate of dNTP synthesis (Plunkett et al, 1996). It has
recently been reported that the physiological factor for ribo-
nucleotide reduction is thioredoxin, which is required for the RR
reaction in vitro (Koc et al, 2006). In yeast, mutants lacking
thioredoxin had significantly lower dNTP levels, supporting the
idea that thioredoxin functions as an RR reductant in vitro.
Interestingly, thioredoxin is identified as a gene whose basal
expression is increased in pancreatic cancer cells in which Smad7
is commonly overexpressed (Arnold et al, 2004). Thioredoxin is
downstream of smad7 in a pathway that acts to promote growth
and induce apoptosis resistance in pancreatic cancer cells. Future
studies are necessary to investigate whether or not thioredoxin is
downregulated in gemcitabine-resistant pancreatic cancer cells.
Previous genomic analysis of pancreatic cancer has been
performed exclusively with surgical and autopsy specimens, owing
to the difficulty of tissue sampling without surgery. To overcome
this difficulty, endoscopic ultrasonography-guided fine-needle
aspiration biopsy (EUS-FNAB) is applied to obtain tumour cells
as an effective and safe method for tissue diagnosis of pancreatic
cancer (Agarwal et al, 2004). More recently, several investigators
have demonstrated that genetic analysis using EUS-FNAB speci-
mens is possible for determination of cancer stage or to improve
the accuracy of diagnosis (Tada et al, 2002; Pellise et al, 2004). The
current study shows that detection and quantitation of hENT1,
dCK, RRM1, and RRM2 mRNA can be performed rapidly and
reliably using light cycler-PCR with SYBR Green fluorescence. The
analytical strategy using light cycler-PCR with EUS-FNAB speci-
mens will enable us to evaluate the chemoresistance of pancreatic
cancer before and after gemcitabine treatment in the clinic.
In summary, quantitative RT–PCR analysis showed that the
balance of four gene expression levels correlates with inherent
and acquired resistance to gemcitabine in pancreatic cancer cells.
We propose that resistance of cancer cells to gemcitabine is
determined by the ratio of expression of these genes in pancreatic
cancer cells. The ratio of gene expression may be a useful marker
for predicting and monitoring the efficacy of gemcitabine therapy
in pancreatic cancer patients. Further studies are currently
underway using pancreatic cancer tissues obtained by EUS-FNAB
to elucidate the importance of the expression ratio in gemcitabine
therapy for pancreatic cancer patients.
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